Shares of PDS Biotechnology Co. (NASDAQ:PDSB – Get Free Report) have been assigned an average rating of “Buy” from the five ratings firms that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $14.25.
Several research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a report on Wednesday, October 2nd. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st.
Get Our Latest Analysis on PDSB
PDS Biotechnology Price Performance
PDS Biotechnology (NASDAQ:PDSB – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same quarter in the prior year, the company posted ($0.37) earnings per share. As a group, research analysts expect that PDS Biotechnology will post -1.24 EPS for the current fiscal year.
Institutional Trading of PDS Biotechnology
A number of hedge funds have recently modified their holdings of PDSB. Inspirion Wealth Advisors LLC increased its holdings in shares of PDS Biotechnology by 5.5% in the first quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company’s stock valued at $1,406,000 after purchasing an additional 18,383 shares during the last quarter. Kathleen S. Wright Associates Inc. acquired a new stake in shares of PDS Biotechnology in the first quarter valued at approximately $28,000. Vanguard Group Inc. increased its holdings in shares of PDS Biotechnology by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after purchasing an additional 82,135 shares during the last quarter. Tempus Wealth Planning LLC acquired a new stake in shares of PDS Biotechnology in the second quarter valued at approximately $55,000. Finally, Ground Swell Capital LLC acquired a new stake in shares of PDS Biotechnology in the second quarter valued at approximately $67,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.
PDS Biotechnology Company Profile
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
See Also
- Five stocks we like better than PDS Biotechnology
- 3 Best Fintech Stocks for a Portfolio Boost
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- What Are Some of the Best Large-Cap Stocks to Buy?
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Most Volatile Stocks, What Investors Need to Know
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.